CareFusion soars in Q4; Accuray seeks $75M as sales drop;

 @FierceMedDev: Ultrasound elastography eyed as cancer Dx method. Report | Follow @FierceMedDev

 @MarkHFierce: India is competing with the larger device companies by launching firms that make cheaper, quality alternatives. News | Follow @MarkHFierce

 @DamianFierce: LabCorp joins the list of diagnostics providers expecting Medicare cuts to take a bite out of 2013 revenue. Story | Follow @DamianFierce

> CareFusion ($CFN) saw its net income soar 14% last quarter, bringing in $192 million on $909 million in sales. Story

> Accuray ($ARAY) is seeking to raise $75 million in debt financing as its sales plummet and debts mount. News

> Covidien ($COV) posted strong two-year safety and efficacy results for its Solitaire FR revascularization device, designed to remove blood clots in patients suffering from strokes. More

> Invacare ($IVC), working to put itself back together after a damaging FDA consent decree, is planning $100 million in cuts to get back to profitability in 2013. Release

> St. Jude Medical ($STJ) released more data on its Amplatzer PFO Occluder, finding that patients treated with the tiny device had fewer, smaller strokes that were less likely to originate from blood clots passing through the patent foramen ovale, an opening in the heart. Item

> California's EndoSee has raised $1.6 million of a $2.5 million round to develop a device that would allow in-office uterine cavity examination. Article

Biotech News

 @FierceBiotech: Pfizer to lop off Asian research unit amid major R&D downsizing. Story | Follow @FierceBiotech

@RyanMFierce: Troubled biotech Tranzyme mulls potential sale after R&D face plants. More | Follow @RyanMFierce

> French biotech rapidly stuck on losing side of hep C revolution. News

> A new wave of biotechs takes shape in the U.K. Editor's Corner

> Oncolytics Biotech surges on lung cancer data. Story

Pharma News

@FiercePharma: Turns out, Vivus' slow launch of Qsymia may be best plan. News | Follow @FiercePharma

@EricPFierce: Sun tells Taro shareholders to forget it, cancels $685 million offer for Israeli generic drug player. Report | Follow @EricPFierce

@AlisonBFierce: Evidence of a link between GSK's Pandemrix and a spike in narcolepsy cases is putting AS03 under intense scrutiny. More | Follow @AlisonBFierce

> Court spoons out good news for Merck investors. Report

> Pfizer cuts some more, closing R&D site in Singapore. Item

Suggested Articles

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.